HA
GH icon

Huntleigh Advisors’s Guardant Health GH Stock Holding History

Huntleigh Advisors’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$456K Buy
+3,041
New +$331K 0.06% 202

Other funds holding GH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Huntleigh Advisors's GH Position: Q2 2026 in Review

Huntleigh Advisors opened a new position in Guardant Health (GH) in Q2 2026: 3,041 shares worth $456K. The stake represents 0.06% of the portfolio and ranks #202 among its holdings.

597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

  • Huntleigh Advisors held 3,041 shares of Guardant Health worth $456K as of Q2 2026.
  • Guardant Health was a new Huntleigh Advisors position in Q2 2026.
  • Guardant Health made up 0.06% of Huntleigh Advisors's portfolio in Q2 2026, its #202 holding.
  • 597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Huntleigh Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.